Aiming to bring personalized medicine to the Australian health system, a consortium of researchers led by the Peter MacCallum Cancer Center in Melbourne plans to do targeted sequencing of 10,000 formalin-fixed, paraffin-embedded tumor samples, using Illumina's MiSeq and TruSeq cancer panel.

Additionally, researchers involved with the project, called Cancer 2015, will evaluate whether targeted sequencing in early-stage cancer can help increase patient survival, quality of life, and cost effectiveness compared to the current standard of care.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.